Steven Schain of Smart-Counsel LLC.
To prevent the “scheduling” of purported “psychedelic compounds” under the Comprehensive Drug Abuse Prevention and Control Act of 1970, 21 U.S.C. Sections 801, Et. Seq (1970) (Controlled Substance Act or act), biotechnology company Panaea Plant Sciences (PPS) sued the Drug Enforcement Administration (DEA) on April 10.
Ranging from plant drugs, like mushroom-derived psilocybin and cactus-derived peyote, to synthetics like Lysergic acid diethylamide (LSD) and Methylenedioxymethamphetamine (MDMA), hallucinogens are increasingly used to treat recognized disorders, including depression, anxiety, and post-traumatic stress disorder (PTSD), and for wellness applications like enhancing emotional empathy, increasing feelings of closeness and promoting thoughtfulness and contemplativeness.
